Barker, Roger A.
,
Article History
Received: 19 February 2019
Accepted: 3 June 2019
First Online: 1 July 2019
Competing interests
: R.A.B. advises Living Cell Technologies, FujiFilm Cellular Dynamics Inc; BlueRock Therapeutics; Novo Nordisk; Sana Therapeutics and Cellino Biotech on their cell-based therapies for PD as well as UCB, Roche and Lundbeck on other aspects of neurodegenerative disorders of the brain. T.P. has received honorary fees from Boston Scientific for peer-to-peer workshops (related to DBS) in 2018 and 2019. T.F. advises Living Cell Technologies on their cell-based therapy, as well as Bial, Profile Pharma, Peptron and Boston Scientific on other aspects of neurodegenerative disorders of the brain. A.B. is a consultant for Novo Nordisk. M.P. is the owner of Parmar Cells AB and co-inventor on US patent applications 15/093,927 owned by Biolamina AB and EP17181588 owned by Miltenyi Biotec. Patent WO 2015/114059 A1 patents the use of BCL2 in reprogramming. S.P. advises Oxford Biomedica and Axovant